Key Takeaways
- Guidance signals a sharp recovery: FY27 revenue guided at INR 650-675 crores with EBITDA margins of 18-20%, a steep climb from Q4's 13-14% run-rate, driven by new capacity and API growth.
- Hyderabad accident still casts a shadow: The facility is fully provided for and not being rebuilt due to legal uncertainty, but insurance settlement is delayed and customer volumes were lost to dormant backup vendors.
- Dahej expansion is the growth engine: A 12,000 MTPA MCC project comes online by end-FY27, ramping from ~30% utilization in Q1 toward full capacity, with CCS commercialization following in Q1 FY28.
- API business doubles as a second leg: API revenue is expected to cross INR 100 crores in FY27, up from ~INR 60 crores, with another INR 8-10 crores in PLI benefits.
- What to watch next quarter: Whether the insurance claim receives an ad hoc payment by end-June, the pace of margin recovery from Q4's depressed base, and any clarity on the Hyderabad legal matter.
The Hyderabad Incident: Fallout & Recovery
- Customer volumes disrupted, not lost: Some customers activated dormant Vendor 2/Vendor 3 because Sigachi could not supply after the accident, but Sigachi remains an approved supplier and expects to regain preferred vendor status and volumes once supply resumes.
- Export mix dropped sharply: Export percentage fell to 65% from 72% last year because February and March exports did not happen, with product diverted to domestic sales instead, due to the Hyderabad disturbance and geopolitical situations.
- Margins compressed by safety spend: Profitability fell because of additional expenditure on safety audits, internal and external audits, customer audits, safety precautions, increased war rates, and production not increasing.
- MCC utilization depressed: Post-accident, the company concentrated more on safety norms, protocols, equipment, and audits, causing production under-utilization at 75-80% at the MCC facility.
- Insurance claim delayed: The claim was expected by March but discussions are ongoing; management expects an ad hoc amount by around June 25th or 30th, with full settlement later, and states there is no under-insurance.
- Hyderabad facility not being rebuilt: Management chose to build at Dahej SEZ instead to avoid wasting time and resources on potential legal delays, since the matter is sub judice and they do not expect any penalty.
- Full provision taken, no further surprises: The Hyderabad facility has been fully provided for; some reversal may occur; no additional surprises or exceptional losses are expected in FY27.
Amit Raj Sinha: "Because it is under legal issues, we didn't want to really delay it because in case we get we pump in money and it gets stuck on some legal issue, unnecessarily time and resources will be wasted."
Capacity Expansion: Dahej, Jhagadia & CCS
- Dahej 12,000 MTPA MCC project on track: COD is expected by end of FY27, with capacity ramp-up planned at ~30% in Q1, 40-50% in Q2, and gradually increasing through the last two quarters.
- CCS facility next in line: Commercialization is expected in the first quarter of FY28, with revenue expected immediately upon commercialization.
- Jhagadia adding incremental capacity: The Jhagadia expansion contributes to the overall capacity base supporting the FY27 revenue guidance.
- Utilization target is ambitious: Management expects overall capacity utilization to rise from the current ~60% to north of 90% this year, with a comfortable target near 95-97%.
- CapEx funding still undecided: The funding mix for the INR 200 crores CapEx is in a fluid stage, with options including internal accruals, term loans, and possibly equity; management will disclose once a resolution is formed.
- Future expansion plans exist but are unannounced: Management stated expansion plans are in place and will be disclosed at the appropriate time.
FY27 Guidance & Margin Trajectory
- Revenue guided at INR 650-675 crores: Supported by incremental capacities from Dahej and Jhagadia, improved product mix, and API growth.
- EBITDA margin guided at 18-20%: A significant recovery from Q4 FY26 margins of around 13-14%, with Q1 and Q2 FY27 expected to gradually increase toward the year-end target.
- H2 seasonality will help: Management stated H2 will be higher than H1, Q2 always more than Q1, and margins will be higher in H2.
- Normalcy timeline extends into FY28: Management expects to return to complete normalcy in margins by FY27 or mid-FY28.
- INR 1,000 crore turnover not imminent: Management clarified this milestone is not expected in FY28, but possibly in FY29 or later.
- Credit rating downgraded post-incident: The profit reduction caused a downgrade, but management hopes it will improve as Q4 profits were good and coming quarters are expected to be good.
Amit Raj Sinha: "Sigachi enters FY27 with stable operations, expansion projects progressing in line with the plans, and an organization that has been meaningfully strengthened over the course of the past one year."
API Business: The Second Growth Engine
- API revenue doubling in FY27: FY26 API revenue was around INR 60 crores; FY27 is expected to exceed INR 100 crores.
- PLI benefits adding tailwind: Another INR 8-10 crores in PLI benefits is expected in FY27.
- Cystic fibrosis API progressing: Chemistry has been cracked and R&D-level work is complete; filing is planned for the current year (FY27), after which the company will discuss with the innovator to determine production timelines.
Customer & Competitive Position
- Stickiness intact despite disruption: Management affirmed customers are definitely sticky, with no second thoughts, but acknowledged that formulation companies always maintain dormant Vendor 2 and Vendor 3 relationships that get activated during supplier disruptions.
- Volume recovery expected: Sigachi expects to regain preferred vendor status and volumes once products are back on track and supply resumes.
- Middle East JV on hold: The joint venture has been kept on hold due to the present global situation, with no revenue from it currently; management expects some clarity maybe after six months.
Amit Raj Sinha: "The customers are definitely sticky. There is no second thoughts on that. However, because this is a very small percentage of the total purchase for a formulation mix... the formulation guys always have Vendor 1, Vendor 2, Vendor 3. And the second and the third vendors are usually kept dormant. And when there's a situation across the supplier, they kind of reactivate the Vendor 2 and the Vendor 3."
Balance Sheet & Shareholding
- Promoters intend to increase shareholding: Promoter shareholding will not come down and will gradually go up, with an intention to return to 48-49% levels.
- Debt reduction underway: Debt will come down further by the end of this year; as and when needed, funds will be sourced and paid off.
- Assets written off pending insurance: Other assets declined because insurance after the accident wrote off those assets; the insurance claim is expected and is in the company's favor.
- New Chief People Officer appointed: Mr. Atul Dhavle joined during the quarter to support building scalable organizations and leadership systems.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY27 revenue | INR 650-675 crores | FY27 full year |
| FY27 EBITDA margin | 18-20% | FY27 full year |
| Dahej 12,000 MTPA MCC COD | COD with ramp-up from ~30% in Q1 to gradual increase through H2 | End of FY27 |
| CCS facility commercialization | Revenue expected immediately upon commercialization | Q1 FY28 |
| API revenue | More than INR 100 crores | FY27 |
| API PLI benefit | INR 8-10 crores | FY27 |
| Capacity utilization | North of 90%, comfortable near 95-97% | FY27 |
| Margin normalcy | Complete normalcy in margins | FY27 to mid-FY28 |
| Insurance ad hoc payment | Ad hoc amount expected | Around June 25-30, 2025 |
| Promoter shareholding | Gradual increase back to 48-49% | No date; intention stated |
| Debt reduction | Further reduction | By end of FY27 |
| INR 1,000 crore turnover | Not in FY28 | Possibly FY29 or later |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Total operating income | ₹121.89 cr |
| EBITDA | ₹15.4 cr, margin 12.63% |
| Net profit | ₹7.6 cr, PAT margin 6.23% |
| FY27 revenue guidance | ₹650-675 cr |
| FY27 EBITDA margin guidance | 18-20% |
| MCC segment revenue | ₹85.33 cr |
| O&M segment revenue | ₹14.63 cr |
| API segment revenue | ₹17.06 cr |
| Cellulose-based excipient sale quantities | 14,857 metric tons |
| MCC capacity utilization | 82% |
| Export turnover | 65% of total revenue, down from 72% last year |
| API FY26 revenue | ~₹60 cr |
| API FY27 expected revenue | >₹100 cr |
| API facility utilization (Grandmax) | 65-70% |
| O&M EBITDA margin | 21-22% |
| MCC 12,000 MT expansion CapEx | ₹106 cr |
| CCS facility total project cost | ₹90 cr |
| Total debt outstanding | ₹145 cr, all working-capital debt |
| Insurance claim expected | ₹53.5 cr fixed-asset and inventory loss, plus ₹16.5 cr business-interruption loss |